1 / 12

Analgesic Drug Development for Chronic Pain A Brief to DAAODP & AAC July 29, 2002

Analgesic Drug Development for Chronic Pain A Brief to DAAODP & AAC July 29, 2002. Najib Babul, PharmD TheraQuest Biosciences nbabul@theraquestinc.com. Conflict of Interest Statement. Pharmaceutical sponsors with submissions or pending submissions before Divisions 550 and 170.

lan
Télécharger la présentation

Analgesic Drug Development for Chronic Pain A Brief to DAAODP & AAC July 29, 2002

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Analgesic Drug Development for Chronic PainA Brief to DAAODP & AACJuly 29, 2002 Najib Babul, PharmD TheraQuest Biosciences nbabul@theraquestinc.com

  2. Conflict of Interest Statement • Pharmaceutical sponsors with submissions or pending submissions before Divisions 550 and 170. • Views expressed are solely those of TheraQuest Biosciences TheraQuest

  3. Analgesic Drug Development: Regulatory Framework FDA • Guideline for the Evaluation of Analgesic Drugs (December, 1992) EMEA • Guidance on Clinical Investigation of Medicinal Products for Treatment of Pain (CPMP Draft, November 2001) TheraQuest

  4. Supportive Guidelines • Clinical development programs for drugs, devices and biological products intended for the treatment of osteoarthritis (FDA Guidance, July 1999) • Clinical investigation of medicinal products used in the treatment of osteoarthritis (CPMP PTC, July 1998) TheraQuest

  5. Gaps in Regulatory Framework • Multidose evaluation in acute pain • Slow-onset drugs with utility in acute pain • Drugs for neuropathic pain • Drugs for cancer pain • Guidance for CLBP, fibromyalgia, myofascial pain • Chronic pain as an indication TheraQuest

  6. Potential Models of Chronic Pain • Myofascial pain • Low back pain • Osteoarthritis • Fibromyalgia • Mixed-model population • Neuropathic pain* • Cancer pain* TheraQuest

  7. Response Assessment in Chronic Pain: Challenges • Diverse etiology • Heterogeneous population within diagnosis • Referral patterns • Psychological overlay • Disability payments and litigation • “Unrealistic” outcomes expectations TheraQuest

  8. It has recently been suggested that replicate evidence in 3 chronic pain states (models) may be required for a chronic pain indication …. What are the potential implications of this?

  9. Chronic Pain Indication • Do we have three well established and robust models of chronic pain? • Replicate evidence for a specific sub-indication may be appropriate • Replication in two models of chronic pain OR robust and internally consistent evidence in single trials in three models may be reasonable • If burden is too high for a broad indication, will we get sub-indications, with attendant off-label use? TheraQuest

  10. Additional Issues • Use of co-primary endpoints - Pain, function, global - Some precedence in OA - Increased statistical burden? - Unrealistic pharmacologic expectation for complex disorders? • Placebo-control vs. active control • Clinimetric flexibility TheraQuest

  11. Important Considerations • DAAODP and DACCADP face somewhat different issues: - Abuse liability, neuropathic pain - GI and CV outcomes, inflammatory pain, disease modification • However, “harmonized” development guidelines may help assure cost-effective development, parity and timely patient access • Sponsors with clinical development/submissions underway may need special considerations

  12. Analgesics Drug Development for Chronic PainA Brief to DAAODP & AACJuly 29, 2002 Najib Babul, PharmD TheraQuest Biosciences nbabul@theraquestinc.com

More Related